AroCell Q2: Good cost control, somewhat lower sales - Redeye
Redeye returns with a more detailed take on the Q2 report and notes lower costs than
expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E
sales somewhat. We reiterate our fair value range.
ANNONS
Redeye returns with a more detailed take on the Q2 report and notes lower costs than
expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E
sales somewhat. We reiterate our fair value range.